Is Revolution Medicines a Good Stock to Own?
Though it’s still quite early in the year, pharmaceutical startup…
Sell
34
RLMD Quote, Financials, Valuation and Earnings
Last price:
$3.79
Seasonality move
:
-2.79%
Day range:
$3.77 - $4.06
52-week range:
$0.24 - $5.12
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
29.75x
Volume:
414K
Avg. volume:
858.1K
1-year change:
859.76%
Market cap:
$281.6M
Revenue:
--
EPS (TTM):
-$1.80
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
RLMD
Relmada Therapeutics, Inc.
|
-- | -- | -- | -- | $6.67 |
|
ACLX
Arcellx, Inc.
|
$12.6M | -$1.04 | -17.12% | -2.29% | $112.35 |
|
FOLD
Amicus Therapeutics, Inc.
|
$179.8M | $0.16 | 20.08% | 234.42% | $14.83 |
|
IVVD
Invivyd, Inc.
|
$15.5M | -$0.10 | 12.27% | -35.02% | $10.00 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
PBYI
Puma Biotechnology, Inc.
|
$68.6M | $0.23 | 16.12% | -41.13% | $3.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
RLMD
Relmada Therapeutics, Inc.
|
$3.84 | $6.67 | $281.6M | -- | $0.00 | 0% | -- |
|
ACLX
Arcellx, Inc.
|
$69.86 | $112.35 | $4B | -- | $0.00 | 0% | 108.18x |
|
FOLD
Amicus Therapeutics, Inc.
|
$14.38 | $14.83 | $4.4B | -- | $0.00 | 0% | 7.36x |
|
IVVD
Invivyd, Inc.
|
$2.60 | $10.00 | $606.1M | -- | $0.00 | 0% | 6.88x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$12.73 | $0.85 | $1.6B | 21.38x | $0.80 | 0% | 24.73x |
|
PBYI
Puma Biotechnology, Inc.
|
$6.42 | $3.50 | $323.5M | 8.67x | $0.00 | 0% | 1.52x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
RLMD
Relmada Therapeutics, Inc.
|
-- | 5.792 | -- | 2.68x |
|
ACLX
Arcellx, Inc.
|
10.52% | 0.763 | 1.09% | 3.90x |
|
FOLD
Amicus Therapeutics, Inc.
|
65.77% | -0.323 | 18.22% | 1.91x |
|
IVVD
Invivyd, Inc.
|
2.8% | -0.921 | 1.14% | 2.13x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | -3.190 | 8.08% | 1.85x |
|
PBYI
Puma Biotechnology, Inc.
|
26.26% | 0.733 | 15.34% | 1.57x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
RLMD
Relmada Therapeutics, Inc.
|
-- | -$10.3M | -214.4% | -214.4% | -- | -$6.7M |
|
ACLX
Arcellx, Inc.
|
$3.1M | -$61.8M | -44.21% | -49.8% | -1248.25% | -$49.5M |
|
FOLD
Amicus Therapeutics, Inc.
|
$147.7M | $34.3M | -2.18% | -7.02% | 20.27% | $35.3M |
|
IVVD
Invivyd, Inc.
|
$11.6M | -$11M | -85.47% | -87.85% | -83.96% | -$8.3M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
PBYI
Puma Biotechnology, Inc.
|
$42.3M | $9.6M | 23.32% | 38.49% | 17.57% | $9.7M |
Relmada Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns RLMD or ACLX?
Arcellx, Inc. has a net margin of -- compared to Relmada Therapeutics, Inc.'s net margin of -1127.12%. Relmada Therapeutics, Inc.'s return on equity of -214.4% beat Arcellx, Inc.'s return on equity of -49.8%.
Company Gross Margin Earnings Per Share Invested Capital RLMDRelmada Therapeutics, Inc.-- -$0.30 $9.5M ACLXArcellx, Inc.62.76% -$0.99 $492.6M -
What do Analysts Say About RLMD or ACLX?
Relmada Therapeutics, Inc. has a consensus price target of $6.67, signalling upside risk potential of 73.61%. On the other hand Arcellx, Inc. has an analysts' consensus of $112.35 which suggests that it could grow by 60.83%. Given that Relmada Therapeutics, Inc. has higher upside potential than Arcellx, Inc., analysts believe Relmada Therapeutics, Inc. is more attractive than Arcellx, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RLMDRelmada Therapeutics, Inc.2 1 0 ACLXArcellx, Inc.15 2 0 -
Is RLMD or ACLX More Risky?
Relmada Therapeutics, Inc. has a beta of 0.772, which suggesting that the stock is 22.834% less volatile than S&P 500. In comparison Arcellx, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock RLMD or ACLX?
Relmada Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arcellx, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Relmada Therapeutics, Inc. pays -- of its earnings as a dividend. Arcellx, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RLMD or ACLX?
Relmada Therapeutics, Inc. quarterly revenues are --, which are smaller than Arcellx, Inc. quarterly revenues of $4.9M. Relmada Therapeutics, Inc.'s net income of -$10.1M is higher than Arcellx, Inc.'s net income of -$55.8M. Notably, Relmada Therapeutics, Inc.'s price-to-earnings ratio is -- while Arcellx, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Relmada Therapeutics, Inc. is -- versus 108.18x for Arcellx, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RLMDRelmada Therapeutics, Inc.-- -- -- -$10.1M ACLXArcellx, Inc.108.18x -- $4.9M -$55.8M
-
Which has Higher Returns RLMD or FOLD?
Amicus Therapeutics, Inc. has a net margin of -- compared to Relmada Therapeutics, Inc.'s net margin of 10.24%. Relmada Therapeutics, Inc.'s return on equity of -214.4% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.
Company Gross Margin Earnings Per Share Invested Capital RLMDRelmada Therapeutics, Inc.-- -$0.30 $9.5M FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M -
What do Analysts Say About RLMD or FOLD?
Relmada Therapeutics, Inc. has a consensus price target of $6.67, signalling upside risk potential of 73.61%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.83 which suggests that it could grow by 3.15%. Given that Relmada Therapeutics, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Relmada Therapeutics, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RLMDRelmada Therapeutics, Inc.2 1 0 FOLDAmicus Therapeutics, Inc.2 5 0 -
Is RLMD or FOLD More Risky?
Relmada Therapeutics, Inc. has a beta of 0.772, which suggesting that the stock is 22.834% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.417, suggesting its less volatile than the S&P 500 by 58.311%.
-
Which is a Better Dividend Stock RLMD or FOLD?
Relmada Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Relmada Therapeutics, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RLMD or FOLD?
Relmada Therapeutics, Inc. quarterly revenues are --, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Relmada Therapeutics, Inc.'s net income of -$10.1M is lower than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Relmada Therapeutics, Inc.'s price-to-earnings ratio is -- while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Relmada Therapeutics, Inc. is -- versus 7.36x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RLMDRelmada Therapeutics, Inc.-- -- -- -$10.1M FOLDAmicus Therapeutics, Inc.7.36x -- $169.1M $17.3M
-
Which has Higher Returns RLMD or IVVD?
Invivyd, Inc. has a net margin of -- compared to Relmada Therapeutics, Inc.'s net margin of -79.75%. Relmada Therapeutics, Inc.'s return on equity of -214.4% beat Invivyd, Inc.'s return on equity of -87.85%.
Company Gross Margin Earnings Per Share Invested Capital RLMDRelmada Therapeutics, Inc.-- -$0.30 $9.5M IVVDInvivyd, Inc.88.43% -$0.06 $95.7M -
What do Analysts Say About RLMD or IVVD?
Relmada Therapeutics, Inc. has a consensus price target of $6.67, signalling upside risk potential of 73.61%. On the other hand Invivyd, Inc. has an analysts' consensus of $10.00 which suggests that it could grow by 284.62%. Given that Invivyd, Inc. has higher upside potential than Relmada Therapeutics, Inc., analysts believe Invivyd, Inc. is more attractive than Relmada Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RLMDRelmada Therapeutics, Inc.2 1 0 IVVDInvivyd, Inc.3 1 0 -
Is RLMD or IVVD More Risky?
Relmada Therapeutics, Inc. has a beta of 0.772, which suggesting that the stock is 22.834% less volatile than S&P 500. In comparison Invivyd, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock RLMD or IVVD?
Relmada Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Invivyd, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Relmada Therapeutics, Inc. pays -- of its earnings as a dividend. Invivyd, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RLMD or IVVD?
Relmada Therapeutics, Inc. quarterly revenues are --, which are smaller than Invivyd, Inc. quarterly revenues of $13.1M. Relmada Therapeutics, Inc.'s net income of -$10.1M is higher than Invivyd, Inc.'s net income of -$10.5M. Notably, Relmada Therapeutics, Inc.'s price-to-earnings ratio is -- while Invivyd, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Relmada Therapeutics, Inc. is -- versus 6.88x for Invivyd, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RLMDRelmada Therapeutics, Inc.-- -- -- -$10.1M IVVDInvivyd, Inc.6.88x -- $13.1M -$10.5M
-
Which has Higher Returns RLMD or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Relmada Therapeutics, Inc.'s net margin of -255.85%. Relmada Therapeutics, Inc.'s return on equity of -214.4% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital RLMDRelmada Therapeutics, Inc.-- -$0.30 $9.5M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About RLMD or NBY?
Relmada Therapeutics, Inc. has a consensus price target of $6.67, signalling upside risk potential of 73.61%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -93.32%. Given that Relmada Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Relmada Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RLMDRelmada Therapeutics, Inc.2 1 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is RLMD or NBY More Risky?
Relmada Therapeutics, Inc. has a beta of 0.772, which suggesting that the stock is 22.834% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.093, suggesting its less volatile than the S&P 500 by 90.725%.
-
Which is a Better Dividend Stock RLMD or NBY?
Relmada Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Relmada Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RLMD or NBY?
Relmada Therapeutics, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Relmada Therapeutics, Inc.'s net income of -$10.1M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Relmada Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 21.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Relmada Therapeutics, Inc. is -- versus 24.73x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RLMDRelmada Therapeutics, Inc.-- -- -- -$10.1M NBYNovaBay Pharmaceuticals, Inc.24.73x 21.38x $521K -$1.3M
-
Which has Higher Returns RLMD or PBYI?
Puma Biotechnology, Inc. has a net margin of -- compared to Relmada Therapeutics, Inc.'s net margin of 16.24%. Relmada Therapeutics, Inc.'s return on equity of -214.4% beat Puma Biotechnology, Inc.'s return on equity of 38.49%.
Company Gross Margin Earnings Per Share Invested Capital RLMDRelmada Therapeutics, Inc.-- -$0.30 $9.5M PBYIPuma Biotechnology, Inc.77.65% $0.17 $156.3M -
What do Analysts Say About RLMD or PBYI?
Relmada Therapeutics, Inc. has a consensus price target of $6.67, signalling upside risk potential of 73.61%. On the other hand Puma Biotechnology, Inc. has an analysts' consensus of $3.50 which suggests that it could fall by -45.48%. Given that Relmada Therapeutics, Inc. has higher upside potential than Puma Biotechnology, Inc., analysts believe Relmada Therapeutics, Inc. is more attractive than Puma Biotechnology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RLMDRelmada Therapeutics, Inc.2 1 0 PBYIPuma Biotechnology, Inc.0 1 0 -
Is RLMD or PBYI More Risky?
Relmada Therapeutics, Inc. has a beta of 0.772, which suggesting that the stock is 22.834% less volatile than S&P 500. In comparison Puma Biotechnology, Inc. has a beta of 1.187, suggesting its more volatile than the S&P 500 by 18.747%.
-
Which is a Better Dividend Stock RLMD or PBYI?
Relmada Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Puma Biotechnology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Relmada Therapeutics, Inc. pays -- of its earnings as a dividend. Puma Biotechnology, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RLMD or PBYI?
Relmada Therapeutics, Inc. quarterly revenues are --, which are smaller than Puma Biotechnology, Inc. quarterly revenues of $54.5M. Relmada Therapeutics, Inc.'s net income of -$10.1M is lower than Puma Biotechnology, Inc.'s net income of $8.8M. Notably, Relmada Therapeutics, Inc.'s price-to-earnings ratio is -- while Puma Biotechnology, Inc.'s PE ratio is 8.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Relmada Therapeutics, Inc. is -- versus 1.52x for Puma Biotechnology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RLMDRelmada Therapeutics, Inc.-- -- -- -$10.1M PBYIPuma Biotechnology, Inc.1.52x 8.67x $54.5M $8.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Has Vistra Stock Gone Up?
Integrated power generation business Vistra (NYSE:VST) surprised investors recently when…
Why Is Amkor Stock Up So Much?
Semiconductor packaging and testing major Amkor (NASDAQ:AMKR) has started 2026…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
67
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Buy
53
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Buy
80
BNR alert for Jan 15
Burning Rock Biotech Ltd. [BNR] is up 18.69% over the past day.
Sell
37
TCOM alert for Jan 15
Trip.com Group Ltd. [TCOM] is down 2.31% over the past day.
Sell
39
DAVE alert for Jan 15
Dave, Inc. [DAVE] is up 3.48% over the past day.
